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Abstract Brain-derived neurotrophic factor (BDNF) is an
abundant neurotrophin in brain and peripheral nerves, where it
affects neural development, survival and repair after injury.
BDNF has been detected in rat and human blood, but the source
of circulating BDNF is not established. BDNF messenger and
peptide were detected in cultured cells and in the culture medium
of human umbilical vein endothelial cells. The expression of
BDNF was up-regulated by elevation of intracellular cAMP and
down-regulated by Ca2+ ionophore, bovine brain extract and
laminar fluid shear stress. These results suggest that vascular
endothelial cells may contribute to circulating BDNF.
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1. Introduction
Neurotrophins form a large family of dimeric polypeptides
that include nerve growth factor, brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3), NT-4/5, NT-6 and
NT-7 [1^3]. They are known to promote the growth, survival
and di¡erentiation of developing neurons in the central and
peripheral nervous system [4]. BDNF also supports the main-
tenance and regeneration of neurons in the central nervous
system (CNS), and enhances the short-term survival of axo-
tomized mammalian retinal ganglion cells [5]. Neurotrophins
are also widely distributed in the peripheral nervous system
[6], and can promote the survival and neurite outgrowth of
placodal and neural crest-derived sensory neurons [7]. BDNF,
given peripherally, accelerates the regenerative sprouting of
injured adult spinal motoneurons and axotomized retinal gan-
glion cells [8]. Therefore, BDNF may be involved in periph-
eral sensory and motor neuron regeneration at the site of
nerve injury.
Although BDNF is highly concentrated in the nervous sys-
tem, it is also present in human and rat plasma (109 and 150
pg/ml, respectively) and is much more concentrated in the
serum [9]. However, the source of circulating BDNF remains
unknown and several candidate cell types are considered in
this report. Human platelets, which contain BDNF mRNA
and release BDNF protein [9,10], might be a source of circu-
lating BDNF. It is established that platelets have limited pro-
tein synthesis capacity, however, many substances (e.g. von
Willebrand factor, ¢brinogen, albumin and serotonin) that
are stored and released by platelets are sequestered from the
blood. Megakaryocytes are the progenitor cells for platelets.
Thus, BDNF could be made by megakaryocytes and passed
to the platelets as they are pinched o¡ of the megakaryocytes.
Alternatively, our recent demonstration of BDNF binding to
platelets suggests that BDNF may be sequestered into plate-
lets rather than synthesized in them [11]. The pituitary gland,
where the anterior and neurointermediate lobes contain
BDNF mRNA [12], could also be a source of circulating
BDNF. However, BDNF levels in rat platelets and sera
were not altered following long-term hypophysectomy (un-
published observation). Several neurotrophins including
BDNF are expressed in non-neuronal organ systems including
developing heart [13], vascular smooth muscle cells [14], devel-
oping intestine [15] and spleen [16], besides platelets. Recently,
activated human T cells, B cells and monocytes have been
found to release BDNF in vitro and in the brain regions of
in£ammatory lesions [17]. In previous studies with platelets,
the expression of BDNF was detected with the polymerase
chain reaction (PCR), a very sensitive method. In the present
study, we investigated and quanti¢ed the expression of BDNF
in vascular endothelial cells, megakaryocytic cells and plate-
lets. It is demonstrated that BDNF is synthesized and secreted
by human umbilical vein endothelial cells (HUVECs), and
that the BDNF expression in HUVECs is regulated by intra-
cellular cyclic adenosine monophosphate (cAMP), bovine
brain extract (BBE) and laminar £uid shear stress.
2. Materials and methods
2.1. Cell culture and platelet preparation
HUVECs were obtained by collagenase (Sigma, St. Louis, MO,
USA) digestion of human umbilical vein as described [18]. The cells
were cultured at 37‡C in Medium 199 with Earle’s salts (Life Tech-
nologies, Rockville, MD, USA), containing 10% fetal calf serum
(FCS), 100 IU/ml penicillin, 100 Wg/ml streptomycin, 0.015% BBE
and 0.01% heparin under humidi¢ed 5% CO2/95% air. BBE was
kindly provided by M. Fong and prepared according to a published
method [19]. Brie£y, 740 g of bovine hypothalamus was homogenized
in 1 l of 0.15 M NaCl at 4‡C for 4 min followed by stirring at 4‡C for
2 h and subsequent centrifugation at 13 800Ug for 40 min. The super-
natant was collected and stirred for approximately 1 h at 4‡C after
adding streptomycin sulfate (Sigma) to a ¢nal concentration of 0.5%
(pH 7.0). The mixture was centrifuged and the supernatant was ¢l-
tered, lyophilized and stored at 320‡C for future use. The second to
the eighth passaged HUVECs were used in the studies. The cells were
sub-cultured using trypsin^EDTA, and seeded onto gelatin (0.2%)-
coated petri dishes (35 mm in diameter) or 6 well plates. Isolated
human coronary artery smooth muscle cells (HCASMCs) were pur-
chased from Clonetics (Walkersville, MD, USA) and maintained in
the medium recommended by the vender. Megakaryocytic cell lines
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(Meg-01, K562) were purchased from ATCC and cultured in F12K
(Life Technologies, Rockville, MD, USA) containing 10% FCS.
Blood was drawn from healthy volunteers and mixed with 1/10
volume of 3.8% sodium citrate, followed by centrifugation at
150Ug for 20 min. Supernatant (platelet rich plasma, PRP) was col-
lected without disturbing bu¡y coat and packed red blood cells. Con-
taminating leukocytes and red blood cells were removed by an addi-
tional centrifugation for 10 min at 150Ug. The pH of resultant PRP
was lowered to 6.5 with citric acid (4 Wl/ml from 1 M stock) prior to
sedimentation of platelets at 800Ug for 15 min. The pellet was used
for RNA extraction.
2.2. Measurement of BDNF with enzyme-linked immunosorbent assay
(ELISA)
When the cells reached con£uence, culture medium was replaced
with 2 ml of new medium after washing the cells three times with
sterile phosphate-bu¡ered saline (PBS, pH 7.4). At 12, 24, 36 and
48 h of incubation, 200 Wl culture medium was collected and frozen
at 370‡C. To study the regulation of BDNF expression, con£uent
HUVECs were changed to new medium without BBE. Then, BBE
(0.015%), interleukin (IL)-1L (10 ng/ml), transforming growth factor
(TGF) L (10 ng/ml), forskolin (1 and 10 WM), thrombin (1 and 4 U/
ml), histamine (10 WM), cycloheximide (CHX, 1 ng/ml), A23187
(1 WM) and 8-bromo-cAMP (500 WM; all above from Sigma) were
added at time 0. At the end of experiments, the supernatants were
collected and stored at 370‡C until measurement. The cells were
washed three times with PBS before being lysed in 200 Wl of 1% Triton
X-100 in 50 mM Tris^HCl (pH 7.5) plus phenylmethylsulfonyl £uo-
ride (1 mM), N-ethylmaleimide (1 mM), leupeptin (2 Wg/ml), NaF
(1 mM), benzamidine (1 mM) and sodium vanadate (Na3VO4,
1 mM; all from Sigma). After incubation on ice for 1 h, the lysates
were centrifuged at 12 000Ug for 30 min. The BDNF in cell culture
medium and cell lysates was measured by a commercial ELISA kit
(Promega). The detection limit (sensitivity) of the ELISA is 15.6 pg/
ml, with a coe⁄cient of variance of 8.8% at a mean concentration of
28.6 pg/ml BDNF, according to the manufacturer’s brochure. It was
noticed that the ELISA measurement of BDNF was a¡ected by the
dilution of samples. In the early experiments, we measured BDNF in
the samples without dilution. The calculated values are lower than
that obtained later when we diluted the samples 1:1 with the ELISA
dilution bu¡er. To test whether BDNF has any autocrine/paracrine
e¡ect on BDNF expression in HUVECs, recombinant human BDNF
(200 pg/ml) was added to the medium without BBE; and neutralizing
chicken polyclonal antibodies against human BDNF were added to
the medium containing BBE (both from Promega, Madison, WI,
USA). For this experiment, BDNF expression was measured by re-
verse transcription and PCR (RT-PCR) (Section 2.3). Data are de-
scribed as the mean þ S.D. Student’s t-test was used for determining
statistical signi¢cance.
2.3. RT-PCR
Total RNA from HUVECs, platelets and other cells was extracted
using RNA Stat-60 kit (Tel-test, Friendswood, TX, USA). The purity
of RNA was determined by spectrophotometric measurements at
260 and 280 nm. One Wg total RNA was reverse-transcribed into
complementary DNA (cDNA) in 20 Wl solution, using a Supertran-
scriptase II kit (Life Technologies). One Wl RT reactions were used for
each PCR ampli¢cation with a pair of speci¢c primers for BDNF
(forward 5P-AGAGTGATGACCATCCTTTTCC-3P and reverse 5P-
GCAGCCTTCTTTTGTGTAACC-3P), and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH, forward 5P-ATCAATGGAAATCC-
CATCACC-3P and reverse 5P-TCTCTTCCTCTTGTGCTCTTGC-3P).
PCR ampli¢cation was performed using a Perkin-Elmer 9700 thermal
cycler for cycles as indicated, consisting of denaturation at 95‡C for
1 min, annealing at the indicated temperature for 30 s and synthesis at
72‡C for 1 min. The annealing temperatures and number of cycles for
BDNF or GAPDH were 55‡C or 55‡C and 32 or 28 cycles, respec-
tively. The PCR products were separated on a 1% agarose gel and
stained with ethidium bromide. The sequence of ampli¢ed DNA frag-
ments was con¢rmed by sub-cloning them into plasmid vector pCR-II
(Invitrogen, Carlsbad, CA, USA) followed by automatic DNA se-
quencing using an ABI 377 sequencer.
2.4. Northern blot analysis
The cDNA fragment of BDNF obtained by RT-PCR from HU-
VECs was labeled with [32P]dCTP by nick translation and used as
probe. Total RNA (20 Wg) was extracted from pooled, fresh human
platelets, cultured HUVECs, HCASMCs, Meg-01 and K562 cells, and
run on a 1% denatured formaldehyde agarose gel. After blotting and
¢xing on a nylon membrane (Immobilon-Ny, Millipore, Medford,
MA, USA), the membrane was incubated with the probe and allowed
to hybridize at 42‡C overnight. The membrane was then washed three
times with 1USSC plus 0.1% sodium dodecyl sulfate (SDS) at 65‡C.
Prior to exposing to X-ray ¢lm, the membrane was washed once with
0.2USSC containing 0.1% SDS.
2.5. Laminar £uid shear stress loading
The shear loading system was modi¢ed from the cone-plate visc-
ometer device, which can load well-de¢ned laminar £uid shear stress
to the cultured HUVECs [20]. The shear stress device consists of a
cone that rotates above a stationary base plate containing the cultured
HUVECs. The base plate is made from a 35 mm diameter gelatin-
coated polystyrene dish (Corning, Marlboro, MD, USA). The cone
makes an angle of 0.5‡ with the base plate; and its rotation is con-
trolled by a motor with adjustable speed. The shear stress device was
operated in a CO2 incubator. Con£uent HUVECs in a 35 mm dish
were washed three times with PBS. 1.15 ml of culture medium was
added. The distance between the cone and the culture dish was ad-
justed to 50 Wm. The HUVECs were then exposed to shear stress (24
dyne/cm2) for 24 h, after 30 min of pre-incubation in the incubator.
Control samples without loading shear stress were obtained by the
same procedure but without rotation.
3. Results
3.1. BDNF production by endothelial cells
BDNF in the HUVEC medium was measured by ELISA.
As shown in Fig. 1, the concentration of BDNF in the me-
dium after 48 h of incubation without BBE ranged from 15.3
to 251 pg/ml with an average of 135 þ 67.2 pg/ml (n = 18).
BDNF in the cell lysates was 52.6 þ 7.0 pg/ml (n = 3). BDNF
in the culture medium was lower when the cells were cultured
with BBE (range from undetectable to 57 pg/ml with an aver-
age of 16.8 þ 14.8 pg/ml, P6 0.01). BDNF in the cell lysates
was also signi¢cantly lower (27.6 þ 13.6 pg/ml, n = 3) than in
cells cultured with BBE (P6 0.05). BDNF was also detected
in the culture media of two other primary endothelial cell
cultures of human coronary artery and bovine pulmonary
artery, with concentrations ranging from 22 to 373 pg/ml
(data not shown). Comparison of the BDNF content inside
the HUVECs (10.5 pg on average in a given petri dish at 48 h)
and the 270 pg BDNF in the culture medium in the absence of
BBE suggests that most of the BDNF synthesized in the
Fig. 1. BDNF synthesis and secretion by cultured HUVECs. HU-
VECs were cultured in the presence of added BBE until con£uency,
and the culture medium was replenished without or with added
BBE. The cells were then washed three times with PBS. The culture
medium was collected after 48 h incubation and the cells were lysed
(see Section 2). BDNF in the culture medium and HUVEC cell ly-
sates was measured by ELISA. *P6 0.01; #P6 0.05.
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HUVECs was constitutively released into the medium. As
shown in Fig. 2A, BDNF concentration in the culture me-
dium increased with time whether in the absence or presence
of BBE. To test whether the BDNF released by HUVECs was
newly synthesized or from a stored pool, CHX (1 ng/ml) was
added to the culture medium to inhibit peptide synthesis.
After 48 h of incubation, signi¢cantly less BDNF (38% of
control, n = 3) was detected in the medium of cells treated
with CHX (Fig. 2B, P6 0.05).
3.2. BDNF mRNA in endothelial cells
The expression of BDNF in HUVECs was further con-
¢rmed using RT-PCR and Northern blot analysis (Fig. 3).
A band at the expected size of 594 bp was ampli¢ed with
speci¢c primers from the cDNA of HUVECs, HCASMCs
and human platelets. The speci¢city of the band was further
con¢rmed by DNA sequencing. Using Northern blot analysis
and a speci¢c probe for BDNF, two strong bands (4.0 and
1.6 kb) were detected in HUVECs and HCASMCs, the same
size bands observed in CNS tissue [21]. In Meg-01 and K562
cells that possess megakaryoblastic properties, the two bands
were barely detected and appeared very faint. No band was
identi¢ed in human platelets, suggesting a very low expression
level of BDNF in the platelets.
3.3. Regulation of BDNF production
An elevation of intracellular cAMP in HUVECs was
achieved with forskolin (1 or 10 WM), which activates adenylyl
cyclase directly. This enhanced the BDNF level in the cell
culture medium by 2.2- and 2.5-fold, respectively (P6 0.01),
as detected by ELISA (Fig. 4). This observation was con-
¢rmed by adding 500 WM 8-bromo-cAMP, a membrane-per-
meable cAMP analogue, which increased BDNF by 2.6-fold
(P6 0.01). The increased release of BDNF by cAMP corre-
sponded with the enhanced BDNF gene expression shown in
Fig. 5. Forskolin increased BDNF mRNA even in the pres-
ence of BBE (4.1-fold, P6 0.005, Fig. 4). Neither IL-1L
(10 ng/ml) nor TGFL (10 ng/ml) a¡ected BDNF expression.
On the other hand, addition of the calcium ionophore A23187
(1 WM) to increase intracellular Ca2 reduced BDNF produc-
tion by HUVEC, to only 2% of the control level obtained
without BBE (P6 0.005, Fig. 4). Thrombin (1 and 4 U/ml)
Fig. 2. A: Time course of BDNF production by HUVECs. The cell culture medium without or with BBE was collected at the time indicated.
BDNF in the medium was measured by ELISA. B: HUVECs were cultured for 48 h in the medium de¢cient of BBE, in the absence (control)
or presence of CHX (1.0 ng/ml). BDNF in the culture medium was assayed by ELISA. *P6 0.01.
Fig. 3. Gene expression of BDNF in HUVECs. A: Detection of BDNF expression by RT-PCR. Equal ampli¢cation of GAPDH in each sam-
ple is shown in the lower panel. Lane 1, 100 bp DNA ladder; lane 2, HUVECs; lane 3, HCASMCs and lane 4, human platelets. Lanes 5,
6 and 7 were negative controls (using pseudo RT for PCR) of lanes 2, 3 and 4, respectively. Pseudo RT products (namely RT without adding
reverse transcriptase) were used with PCR, and did not identify genomic DNA contamination. B: Northern blot analysis of BDNF expression.
Lane 1, HCASMCs; lane 2, HUVECs; lane 3, human platelets; lane 4, Meg-01 cells and lane 5, K562 cells.
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and histamine (10 WM), both of which are known to mediate a
transient Ca2 increase in HUVECs, did not a¡ect BDNF
expression (data not shown). As noted previously (Figs. 1
and 2A), the addition of BBE in cell culture also reduced
BDNF release from HUVECs to V15% of the control with-
out BBE (P6 0.001, Fig. 4) and inhibited BDNF gene expres-
sion (Fig. 5). Addition of exogenous BDNF (200 pg/ml) to the
culture medium de¢cient in BBE, or the addition of BDNF
neutralizing polyclonal antibodies (20 Wg/ml) to the medium
containing BBE, did not a¡ect BDNF gene expression in the
HUVECs (Fig. 5).
3.4. BDNF expression under laminar shear stress
The expression of many genes in HUVECs is regulated by
physiological levels of shear stress as reviewed by Davies [22].
Compared to control (stationary) cells, the release of BDNF
into the culture medium was reduced with 24 h of shear stress
loading to 62% of control (P6 0.05, n = 10, data not shown).
4. Discussion
BDNF gene expression has been reported in non-nervous
tissues including human platelets [10], vascular smooth muscle
cells [14] and activated lymphocytes and monocytes [17]. In
the present study, the expression of BDNF was also demon-
strated in vascular endothelial cells. Our results implicate
BDNF mRNA and protein release for the ability of endothe-
lial cells to promote neuron growth in co-culture [23]. In this
report, however, the BDNF level in cell culture medium meas-
ured by ELISA was nearly 3-fold higher than our values. The
di¡erence may be explained by the di¡erent ELISA kit (Prom-
ega vs. Regeneron) used for BDNF measurement and the
di¡erent media used for the cell culture procedures. It was
also observed that the passage number and HUVEC seeding
density also a¡ected BDNF expression. As the passage num-
ber increased, less and less BDNF was detected in the culture
medium.
The BBE used in our culture medium dramatically inhibited
BDNF expression (by V60%, Fig. 5B). This suppression is
not due to feedback inhibition by BDNF that is probably
contained in the BBE, since adding exogenous BDNF did
not a¡ect BDNF gene expression by HUVECs. Instead, these
results suggest that there may be endogenous inhibitor(s) for
BDNF expression in the CNS, which may regulate BDNF
expression in vivo, and warrant further investigation.
As demonstrated by Northern blot analysis and RT-PCR,
the expression levels of BDNF in human platelets, Meg-01
cells and K562 cells were very low. Almost no BDNF protein
was detected in the cell culture medium or in cell lysates of
Meg-01 and K562, whereas the BDNF content of human
platelets or that released after platelet activation is in the
range of multiple ng/108 platelets [11]. Together, our results
support the hypothesis that most of the BDNF present in
platelets is sequestered from blood, and that vascular endo-
thelial cells may be one of the major sources of BDNF in
platelets and thus in circulation.
The BDNF expression of neuronal and neuron support cells
has been shown to be regulated by cAMP. In cultured rat
Schwann cells, forskolin or 8-bromo-cAMP suppress BDNF
expression [24]. However, elevations of cAMP increase BDNF
expression in neurons of the rat frontal cortex and hippocam-
pus [25]. The cAMP responsive element binding protein has
been implicated in the up-regulation of BDNF expression [26].
DNA sequence analysis identi¢ed a putative cAMP responsive
element (5P-TGACTTCA-3P) in the promoter region of the
BDNF gene (at 31682). A similar up-regulation of HUVEC
BDNF expression by forskolin or 8-bromo-cAMP was ob-
served in the present study. It is known that elevation of
intracellular Ca2 in HUVECs increases the release of many
substances including nitric oxide and prostacyclin (PGI2). Our
results showed that calcium ionophore inhibited BDNF pro-
duction, whereas thrombin or histamine had no e¡ect on
BDNF generation in HUVECs. DNA sequence analysis of
Fig. 4. Regulation of BDNF production in HUVECs. HUVECs
were cultured with the indicated stimuli for 48 h, and BDNF in the
culture medium was measured by ELISA. BDNF concentration in
the culture medium without BBE was used to normalize the data.
Bars show the fold increase from control and error bars show
S.D.s. *P6 0.01 vs. control; 8P6 0.05 vs. +BBE.
Fig. 5. Regulation of BDNF gene expression in HUVECs detected
by RT-PCR. (A) BDNF and GAPDH expression in HUVECs.
HUVECs were harvested for total RNA extraction (and subsequent
RT-PCR) after 24 h culture in the medium de¢cient of BBE (lane
2), plus 200 pg/ml exogenous BDNF (lane 3), or plus 10 mM for-
skolin (lane 4), or in the medium with BBE (lane 5), or with BBE
and 20 Wg/ml polyclonal neutralizing antibodies against BDNF (lane
6). Lane 1, DNA ladder. (B) Densitometry of PCR products from
(A). The data were expressed as ratio of BDNF/GAPDH. The value
for the cells cultured in BBE de¢cient medium was taken as one for
normalization. n = 4, *P6 0.01; #P6 0.05.
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the BDNF gene also indicates the presence of a shear stress
responsive element (5P-GAGACC-3P) [27] in the promoter re-
gion (at 3421) and in the ¢rst intron (at +595 and +629).
Indeed, exposure of HUVECs to physiological levels of shear
stress down-regulated BDNF expression, similar to that seen
with endothelin [28]. Although the physiological signi¢cance
of the down-regulation by shear stress is unclear, changes in
shear stress have been reported to have a close relation to
atherosclerosis. It was observed that atherosclerosis occurred
at the low shear stress area in the aorta [29].
The cardiovascular role of BDNF is unknown. BDNF
functions through a speci¢c high-a⁄nity receptor of tropo-
myosin receptor-related kinase (Trk) B, which is a transmem-
brane tyrosine kinase. The expression of TrkB has been re-
ported in cultured rat and human vascular smooth muscle
cells [14,30]. TrkB expression in smooth muscle cells is found
in human coronary atherosclerotic lesions, and increases dra-
matically in the area of injury and persists during the forma-
tion of the neointima in a rat aortic balloon de-endotheliali-
zation model [14]. Only truncated TrkB which lacks the
tyrosine kinase domain was detected in HUVECs by RT-
PCR (unpublished observations). It is interesting to note
that platelets release large amounts of BDNF rapidly upon
activation by thrombin, calcium ionophore or collagen [11],
which probably occurs at the site of vascular injury as well.
BDNF released in this manner or released from endothelial
cells could bind to TrkB on smooth muscle cells or endothelial
cells, but the functional e¡ects of the binding remain to be
determined. Our data suggest that vascular endothelial cells
are a source of circulating BDNF in the blood.
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